Tau aggregates as immunotherapeutic targets.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Frontiers in Bioscience

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2741/S381PMID 23277060
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease

  2014cited by this paper
• Identification of oligomers at early stages of tau aggregation in Alzheimer's disease

  2012cited by this paper
• Are Tangles as Toxic as They Look?

  2011cited by this paper
• Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models

  2011influential reference
• Tau-Induced Defects in Synaptic Plasticity, Learning, and Memory Are Reversible in Transgenic Mice after Switching Off the Toxic Tau Mutant

  2011cited by this paper
• Recent advances in the development of immunotherapies for tauopathies.

  2011cited by this paper
• In Vivo Microdialysis Reveals Age-Dependent Decrease of Brain Interstitial Fluid Tau Levels in P301S Human Tau Transgenic Mice

  2011cited by this paper
• Immunotherapy for Alzheimer’s disease

  2011cited by this paper
• Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

  2011cited by this paper
• The pathological process underlying Alzheimer’s disease in individuals under thirty

  2011cited by this paper
• Immunotherapy for Tauopathies

  2011cited by this paper
• Alzheimer's disease.

  2011cited by this paper
• Amyloid-β Forms Fibrils by Nucleated Conformational Conversion of Oligomers

  2011cited by this paper
• Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies.

  2011cited by this paper
• Characterization of Prefibrillar Tau Oligomers in Vitro and in Alzheimer Disease*

  2011cited by this paper
• S3‐03‐05: Transmission and Spreading of Tauopathy in Transgenic Mouse Brain

  2011cited by this paper
• Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model

  2011cited by this paper
• Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice

  2011cited by this paper
• Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice.

  2010cited by this paper
• Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease

  2010cited by this paper
• Tau oligomers and aggregation in Alzheimer’s disease

  2010cited by this paper
• Interneuronal Transfer of Human Tau Between Lamprey Central Neurons in situ

  2010cited by this paper
• 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

  2010cited by this paper
• Prion-like mechanisms in neurodegenerative diseases

  2010cited by this paper
• Tau‐tubulin kinase 1 enhances prefibrillar tau aggregation and motor neuron degeneration in P301L FTDP‐17 tau‐mutant mice

  2010cited by this paper
• Preparation and characterization of neurotoxic tau oligomers.

  2010cited by this paper
• Alzheimer's disease: clinical trials and drug development

  2010cited by this paper
• Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model

  2010cited by this paper
• Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions

  2010cited by this paper
• Prion-like transmission of protein aggregates in neurodegenerative diseases

  2010cited by this paper
• Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders.

  2009cited by this paper
• Conformational Diversity of Wild-type Tau Fibrils Specified by Templated Conformation Change*

  2009cited by this paper
• The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics

  2009cited by this paper
• Hippocampal tau pathology is related to neuroanatomical connections: an ageing population-based study.

  2009cited by this paper
• Isolation and Biochemical Characterization of Amyloid Plaques and Paired Helical Filaments

  2009cited by this paper
• Age-Dependent Impairment of Cognitive and Synaptic Function in the htau Mouse Model of Tau Pathology

  2009cited by this paper
• Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders

  2009cited by this paper
• The role of microglia in antibody-mediated clearance of amyloid-beta from the brain.

  2009cited by this paper
• Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease

  2009cited by this paper
• A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.

  2008cited by this paper
• Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies

  2008cited by this paper
• Evidence that Non-Fibrillar Tau Causes Pathology Linked to Neurodegeneration and Behavioral Impairments

  2008cited by this paper
• Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.

  2008cited by this paper
• Current approaches in the treatment of Alzheimer's disease.

  2008cited by this paper
• Frequent amyloid deposition without significant cognitive impairment among the elderly.

  2008cited by this paper
• Tau-based treatment strategies in neurodegenerative diseases

  2008cited by this paper
• Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.

  2008cited by this paper
• Non-tau based neuronal degeneration in Alzheimer's disease -- an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex.

  2008cited by this paper
• Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function.

  2008cited by this paper
• Inhibition and modulation of γ-secretase for Alzheimer’s disease

  2008cited by this paper
• Nucleation-dependent Tau Filament Formation

  2008cited by this paper
• Cholinesterase Inhibitors in Mild Cognitive Impairment: A Systematic Review of Randomised Trials

  2007cited by this paper
• Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements

  2007cited by this paper
• Molecules that Target beta‐Amyloid

  2007cited by this paper
• Tau-mediated neurodegeneration in Alzheimer's disease and related disorders

  2007influential reference
• Tau protein abnormalities associated with the progression of alzheimer disease type dementia.

  2007influential reference
• Granular tau oligomers as intermediates of tau filaments.

  2007cited by this paper
• Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model.

  2007influential reference
• Accumulation of Pathological Tau Species and Memory Loss in a Conditional Model of Tauopathy

  2007cited by this paper
• Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease.

  2006cited by this paper
• Tau Phosphorylation, Aggregation, and Cell Toxicity

  2006cited by this paper
• An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice.

  2006cited by this paper
• Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy.

  2006cited by this paper
• Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein.

  2006cited by this paper
• Extracellular tau is toxic to neuronal cells

  2006cited by this paper
• 100 Years and Counting: Prospects for Defeating Alzheimer's Disease

  2006cited by this paper
• Immunotherapy for conformational diseases.

  2006cited by this paper
• P1–062: Alzheimer's disease–like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits

  2006cited by this paper
• Tau-Positive Fine Granules in the Cerebral White Matter: A Novel Finding Among the Tauopathies Exclusive to Parkinsonism-Dementia Complex of Guam

  2005cited by this paper
• Changed Conformation of Mutant Tau-P301L Underlies the Moribund Tauopathy, Absent in Progressive, Nonlethal Axonopathy of Tau-4R/2N Transgenic Mice*

  2005cited by this paper
• Infectious disease: Unravelling SARS lethality

  2005influential reference
• Cell-Cycle Reentry and Cell Death in Transgenic Mice Expressing Nonmutant Human Tau Isoforms

  2005cited by this paper
• Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease

  2004cited by this paper
• [Therapy of Alzheimer disease].

  2004cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Template-assisted filament growth by parallel stacking of tau.

  2004cited by this paper
• Retarded Axonal Transport of R406W Mutant Tau in Transgenic Mice with a Neurodegenerative Tauopathy

  2004cited by this paper
• Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

  2003cited by this paper
• Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms

  2003cited by this paper
• Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

  2003cited by this paper
• Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model

  2002cited by this paper
• Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning.

  2002cited by this paper
• Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau

  2002cited by this paper
• Neurodegeneration with Tau Accumulation in a Transgenic Mouse Expressing V337M Human Tau

  2002cited by this paper
• Reversible Memory Loss in a Mouse Transgenic Model of Alzheimer's Disease

  2002cited by this paper
• Tau aggregation in the hippocampal formation: an ageing or a pathological process?

  2002cited by this paper
• FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells.

  2002cited by this paper
• FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain.

  2001cited by this paper
• Neurodegenerative tauopathies.

  2001cited by this paper
• Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.

  2001cited by this paper
• Tau Filament Formation in Transgenic Mice Expressing P301L Tau*

  2001cited by this paper
• Tauopathy in Drosophila: Neurodegeneration Without Neurofibrillary Tangles

  2001cited by this paper
• Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.

  2001cited by this paper
• A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

  2000cited by this paper
• Nucleated conformational conversion and the replication of conformational information by a prion determinant.

  2000cited by this paper
• Tau protein isoforms, phosphorylation and role in neurodegenerative disorders.

  2000cited by this paper
• Do neuronal inclusions kill the cell?

  2000cited by this paper
• A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.

  2000cited by this paper
• Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein

  2000influential reference
• Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein

  2000cited by this paper

• Molecular mechanisms of aging in the pathogenesis of Alzheimer’s disease

  2026cites this paper
• A Cannabinoid Type 1 Receptor Antagonist Impairs Spatial Memory and Increases the Tau Gene Expression in an Animal Model of the Alzheimer's Disease.

  2024cites this paper
• Hypoxia: The “Invisible Pusher” of Gut Microbiota

  2021cites this paper
• Phos‐tau peptide immunization of amyloid‐tg‐mice reduced non‐mutant phos‐tau pathology, improved cognition and reduced amyloid plaques

  2018cites this paper
• Soluble tau aggregates, not large fibrils, are the toxic species that display seeding and cross‐seeding behavior

  2018cites this paper
• Potential Neuroprotective Strategies for Concussion and Chronic Traumatic Encephalopathy

  2018cites this paper
• Immunotherapy for the Treatment of Alzheimer’s Disease

  2017cites this paper
• The Potential of Small Molecules in Preventing Tau Oligomer Formation and Toxicity

  2017cites this paper
• Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage

  2017cites this paper
• Isoflurane anesthesia exacerbates learning and memory impairment in zinc-deficient APP/PS1 transgenic mice.

  2016cites this paper
• Tau Immunotherapy Modulates Both Pathological Tau and Upstream Amyloid Pathology in an Alzheimer's Disease Mouse Model

  2015cites this paper
• Long-Term Consequences of Traumatic Brain Injury: Current Status of Potential Mechanisms of Injury and Neurological Outcomes

  2015cites this paper
• Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies.

  2015cites this paper
• The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration

  2015cites this paper
• Amyloid β and Tau Alzheimer’s disease related pathology is reduced by Toll-like receptor 9 stimulation

  2014cites this paper
• First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model

  2014cites this paper
• Specific Targeting of Tau Oligomers in Htau Mice Prevents Cognitive Impairment and Tau Toxicity Following Injection with Brain-Derived Tau Oligomeric Seeds

  2014cites this paper
• Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-Modifying Drugs. Update 2014

  2014cites this paper
• Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles

  2014cites this paper
• A Generic Method for Design of Oligomer-Specific Antibodies

  2014cites this paper
• Novel immunological approaches for the treatment of Alzheimer's disease.

  2014cites this paper
• Protein phosphorylation in neurodegeneration: friend or foe?

  2014cites this paper
• Immunotherapy for Alzheimer's disease.

  2014cites this paper
• Advances in therapeutics for neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species.

  2014cites this paper
• Conformation-Dependent Antibodies as Tools for Characterization of Amyloid Protein Aggregates

  2014cites this paper
• Cellular impedance assays for predictive preclinical drug screening of kinase inhibitor cardiovascular toxicity.

  2013cites this paper
• Immunomodulation targeting of both Aβ and tau pathological conformers ameliorates Alzheimer’s disease pathology in TgSwDI and 3xTg mouse models

  2013cites this paper
• Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target?

  2013cites this paper
• Rapid Accumulation of Endogenous Tau Oligomers in a Rat Model of Traumatic Brain Injury

  2013cites this paper
• Formation and Propagation of Tau Oligomeric Seeds

  2013cites this paper
• What Renders TAU Toxic

  2013cites this paper
• Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

  2013cites this paper
• Tau Oligomers in Traumatic Brain Injury 1 Rapid Accumulation of Endogenous Tau Oligomers in a Rat Model of Traumatic Brain Injury : Possible Link Between TBI and Sporadic Tauopathies

  2013cites this paper
• Alzheimer's disease imaging with a novel Tau targeted near infrared ratiometric probe.

  2013cites this paper
• What rendersTAU toxic

  2013cites this paper